Connor, Clark & Lunn Investment Management (CC&L)
CSTL icon

Connor, Clark & Lunn Investment Management (CC&L)’s Castle Biosciences CSTL Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.91M Sell
331,727
-45,355
-12% -$1.01M 0.02% 598
2026
Q1 		$9.26M Sell
377,082
-11,409
-3% -$374K 0.02% 491
2025
Q4 		$15.1M Buy
388,491
+52,600
+16% +$1.7M 0.04% 352
2025
Q3 		$7.65M Buy
335,891
+209,460
+166% +$4.25M 0.02% 473
2025
Q2 		$2.58M Sell
126,431
-50,458
-29% -$934K 0.01% 782
2025
Q1 		$3.54M Buy
176,889
+8,176
+5% +$202K 0.02% 588
2024
Q4 		$4.5M Buy
168,713
+3,255
+2% +$99.1K 0.02% 508
2024
Q3 		$4.72M Buy
165,458
+98,571
+147% +$2.51M 0.02% 447
2024
Q2 		$1.46M Sell
66,887
-10,770
-14% -$240K 0.01% 753
2024
Q1 		$1.72M Sell
77,657
-10,913
-12% -$237K 0.01% 720
2023
Q4 		$1.91M Buy
88,570
+7,985
+10% +$141K 0.01% 678
2023
Q3 		$1.36M Buy
80,585
+19,040
+31% +$333K 0.01% 726
2023
Q2 		$844K Buy
61,545
+19,363
+46% +$392K ﹤0.01% 847
2023
Q1 		$958K Buy
42,182
+14,038
+50% +$343K 0.01% 724
2022
Q4 		$663K Buy
28,144
+5,053
+22% +$117K ﹤0.01% 806
2022
Q3 		$602K Buy
23,091
+3,628
+19% +$102K ﹤0.01% 778
2022
Q2 		$427K Buy
+19,463
New +$452K ﹤0.01% 816

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s CSTL Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) reduced its Castle Biosciences (CSTL) stake by 12% in Q2 2026, selling an estimated $1.01M and leaving 331,727 shares worth $7.91M. The position accounts for 0.02% of the portfolio, ranked #598.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in CSTL in Q2 2022 and has held it in 17 quarters since. The position peaked at $15.1M in Q4 2025. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 331,727 shares of Castle Biosciences worth $7.91M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) sold 45,355 Castle Biosciences shares in Q2 2026, an estimated $1.01M.
  • Castle Biosciences made up 0.02% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #598 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Castle Biosciences in Q2 2022 and has held it in 17 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Castle Biosciences position peaked at $15.1M in Q4 2025.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.